Cargando…
When to Initiate Weight Loss Medications in the NAFLD Population
Nonalcoholic fatty liver disease (NAFLD) is characterized by histological evidence of hepatic steatosis, lobular inflammation, ballooning degeneration and hepatic fibrosis in the absence of significant alcohol use and other known causes of chronic liver diseases. NAFLD is subdivided into nonalcoholi...
Autores principales: | Yoo, Eric R., Sallam, Sandy, Perumpail, Brandon J., Iqbal, Umair, Shah, Neha D., Kwong, Waiyee, Cholankeril, George, Kim, Donghee, Ahmed, Aijaz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313489/ https://www.ncbi.nlm.nih.gov/pubmed/30274326 http://dx.doi.org/10.3390/diseases6040091 |
Ejemplares similares
-
Judicious Use of Lipid Lowering Agents in the Management of NAFLD
por: Iqbal, Umair, et al.
Publicado: (2018) -
Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD
por: Perumpail, Brandon J., et al.
Publicado: (2018) -
Anti-Diabetic Medications for the Pharmacologic Management of NAFLD
por: Cholankeril, Rosann, et al.
Publicado: (2018) -
The Role of Vitamin E in the Treatment of NAFLD
por: Perumpail, Brandon J., et al.
Publicado: (2018) -
The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD
por: Perumpail, Brandon J., et al.
Publicado: (2019)